Business Wire

MN-KINDEVA-DRUG-DELIVERY

29.5.2024 14:01:30 CEST | Business Wire | Press release

Share
Kindeva Global Health Security Donates ATNAA to Ukraine Through the European Commission's rescEU and Governmental Strategic Reserves Agency (RARS)

Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection Mechanism to aid civilians affected by the war in Ukraine.1 Medical countermeasures (MCMs), such as the ATNAA (Antidote Treatment Nerve Agent Autoinjector), are instrumental in protecting the lives of civilians and military in the event of a chemical nerve agent attack.

This donation was coordinated with the European Commission, which in 2022, established an operational system under the EU Civil Protection Mechanism to channel in-kind donations from the private sector to Ukraine, Moldova, and neighboring EU countries. Via the EU Civil Protection Mechanism, the EU coordinates emergency supply items, therapeutics and medicines, medical devices, shelter items, and more from private and public companies and entities and non-EU governmental institutions that become part of the rescEU reserve to offer an additional layer of protection when disasters strike. The Governmental Strategic Reserves Agency (RARS) in Poland acts on behalf of the European Commission and rescEU to receive the donation and arrange for local transport to Ukraine.

“The rescEU reserve allows the EU to respond more quickly to medical needs caused by health crises, like the war in Ukraine,” said Kindeva’s Tom Handel, Commercial Head - Injectables & Health Security. “Meridian Medical Technologies (Meridian), which merged with Kindeva Drug Delivery in December 2022 to create a leading drug-device CDMO, is the global health security business unit of Kindeva. The company has been putting emergency care treatment options into the hands of military and civilian defenders for more than 60 years and will continue to do so as a combined organization. Kindeva is pleased we were able to work with the European Commission to donate our chemical nerve agent antidote autoinjectors to boost Ukraine’s CBRN stockpile.”

For more information about what items can be donated, visit European Civil Protection and Humanitarian Aid Operations.

About Kindeva Drug Delivery

Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.

1 The delivered goods are meant for emergency aid to Ukraine and are not intended for commercial use in the EU.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529437096/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SWISSto12 passes critical design review of dual-band 5G antennas for UNIVITY satellites9.11.2026 09:00:00 CET | Press release

The milestone clears the way for flight hardware production, bringing UNIVITY closer to delivering both broadband and direct-to-device 5G services from a single satellite architecture. SWISSto12, a leading enabler of the new space economy, today announced it has passed the Critical Design Review (CDR) for the S- and Ka-band phased array antennas for UNIVITY’s 5G non-terrestrial network (NTN) demonstration satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109823601/en/ SWISSto12's S- and Ka-band phased array antennas pass Critical Design Review SWISSto12 is developing two active antennas for UNIVITY: an S-band direct radiating array (DRA) for direct-to-device services, connecting standard 5G phones straight to the satellite, and a Ka-band DRA operating at 26 GHz for broadband services and feeder links. Both are built for 5G NTN applications, allowing one single satellite to carry both broadband and direct-to-devic

Arrow Electronics lancerer en ny forretning, Capstone, for at øge fokus på IP&E-løsninger9.11.2026 07:00:00 CET | Pressemeddelelse

Arrow præsenterer den nye forretning på electronica-messen i München (10.-13. nov) Arrow Electronics, Inc. (NYSE:ARW) annoncerede i dag lanceringen af Capstone, en global forretning dedikeret til interconnect, passiver og elektromekaniske (IP&E) produkter, løsninger og services. Med Capstone skaber Arrow en fokuseret og specialiseret go-to-market-tilgang for IP&E idet det teknologisegment bliver mere kritisk for systemets ydeevne, pålidelighed og forsynings sikkerhed. Capstone er designet til at gøre IP&E nem at specificere, indkøbe og skalere. Kunder vil få fordelen ved dedikeret IP&E ressourcer, hurtig beslutningstagning og bred teknisk viden, både på on-board og off-board produkter. Med et fokuseret brand kan Capstone tilbyde kunderne mere målrettet rådgivning og støtte gennem hele processen – fra de første designovervejelser til den færdige produktion. Det giver kunderne et bedre grundlag for at træffe de rigtige beslutninger, mindske risikoen undervejs og skabe de bedste skalerbar

Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe9.11.2026 07:00:00 CET | Press release

Zemcelpro is authorised in the European Union for eligible adults with blood cancers who need an allogeneic stem cell transplant and have no other suitable donor cells available. Avanzanite secures exclusive commercialisation rights to Zemcelpro across 32 countries covering the European Economic Area, UK and Switzerland including potential indication expansion. Avanzanite will become the EU marketing authorisation holder following regulatory transfer and support a planned Phase 3 trial. Zemcelpro becomes Avanzanite’s fifth rare disease launch and first advanced therapy medicinal product (ATMP). Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commissi

GigaDevice to Showcase Intelligent Embedded Solutions at electronica 20269.11.2026 07:00:00 CET | Press release

Experience Intelligent Motion Through Real-World Applications in Robotics, Industrial, Automotive, and Computing GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will showcase its latest embedded technologies and application-oriented solutions at electronica 2026. As the company continues to strengthen its presence in Europe, the exhibition provides an opportunity to engage with regional customers and partners and demonstrate solutions addressing evolving needs across industrial automation, automotive electronics, and intelligent computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261108191898/en/ Experience Intelligent Motion at Electronica Munich “Europe is an important market for GigaDevice, with strong demand for innovation across industrial automation and automotive electronics,” said Dr. Reiner Jumpertz, Vice President and Gene

Sceye og SoftBank Corp. indgår aftale om en flåde af stratosfæriske platforme, der skal sikre dækning i hele Japan9.11.2026 02:38:00 CET | Pressemeddelelse

Den femårige aftale bygger videre på Sceyes vellykkede test af stratosfærisk forbindelse i Japan og tager et skridt nærmere fuld udrulning af HAPS som stratosfærisk infrastruktur og som en hjørnesten i SoftBanks strategi om et allestedsnærværende netværk Sceye, en amerikansk virksomhed inden for rumfart og materialeteknologi, der udvikler højtflyvende platformssystemer (HAPS) til infrastruktur i stratosfæren, annoncerede i dag en femårig rammeaftale (MSA) med SoftBank Corp. (TOKYO:9434, "SoftBank") om at fremstille, opsende og drive en flåde af Sceyes HAPS-platforme over Japan med det mål at opnå dækning i hele landet. Aftalen videreudvikler virksomhedernes partnerskab fra demonstrationsflyvninger til fuldt udbygget infrastruktur i stratosfæren. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261103165280/da/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye